Vytrus Biotech, S.A. (BME:VYT)

Market Cap	93.30M +391.0%
Revenue (ttm)	8.09M +54.4%
Net Income	1.95M +180.2%
EPS	n/a
Shares Out	7.52M
PE Ratio	47.79
Forward PE	35.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,782
Average Volume	14,464
Open	12.20
Previous Close	12.00
Day's Range	12.20 - 12.60
52-Week Range	2.60 - 13.30
Beta	0.06
RSI	60.64
Earnings Date	Mar 26, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 37
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: VYT

Financial Performance

In 2024, Vytrus Biotech's revenue was 6.09 million, an increase of 29.51% compared to the previous year's 4.70 million. Earnings were 1.02 million, an increase of 87.36%.